Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alzheimer’s and Parkinson’s diseases, along with Robert Glanzman, chief medical officer of Clene Nanomedicine Inc. Hosted on Acast. See <a style="color: grey;" href="https://acast.com/privacy" target= "_blank" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alzheimer’s and Parkinson’s diseases, along with Robert Glanzman, chief medical officer of Clene Nanomedicine Inc. Hosted on Acast. See acast.com/privacy for more information.

Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alzheimer’s and Parkinson’s diseases, along with Robert Glanzman, chief medical officer of Clene Nanomedicine Inc. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs

One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.

Share Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs

Sign up to save your podcasts

Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs

Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs